They are suitable for long-term use and align well with the chronic nature of GLP-1 therapy
Clinical studies show that GLP-1RA therapy decreases circulating MMP-9 and C-reactive protein (CRP) while increasing TIMP-1 and osteoprotegerin (OPG), indicating concurrent suppression of inflammation and attenuation of proteolytic vascular injury (4)
Retatrutide is not FDA approved, not EMA approved, and has no approved prescription pathway as of April 2026
Why this matters: Forcing solvent directly onto the peptide cake at high speed can cause localized denaturation or foaming, which can reduce bioactivity
At the starting dose of 0.25mg weekly, one vial provides 40 weekly doses, though reconstituted semaglutide should be used within 28 days for optimal potency
Examples of GLP-1s include semaglutide (Wegovy), and liraglutide (Saxenda)